Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) EBITDA: 2014-2025

Historic EBITDA for Zevra Therapeutics (ZVRA) over the last 11 years, with Sep 2025 value amounting to $4.1 million.

  • Zevra Therapeutics' EBITDA rose 115.17% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$87.7 million, marking a year-over-year decrease of 1.07%. This contributed to the annual value of -$87.0 million for FY2024, which is 75.40% down from last year.
  • As of Q3 2025, Zevra Therapeutics' EBITDA stood at $4.1 million, which was up 105.83% from -$71.0 million recorded in Q2 2025.
  • Zevra Therapeutics' EBITDA's 5-year high stood at $7.0 million during Q1 2021, with a 5-year trough of -$71.0 million in Q2 2025.
  • Its 3-year average for EBITDA is -$19.0 million, with a median of -$15.4 million in 2023.
  • Per our database at Business Quant, Zevra Therapeutics' EBITDA surged by 284.37% in 2021 and then slumped by 590.21% in 2023.
  • Quarterly analysis of 5 years shows Zevra Therapeutics' EBITDA stood at -$2.8 million in 2021, then crashed by 221.67% to -$9.1 million in 2022, then slumped by 65.80% to -$15.2 million in 2023, then fell by 1.71% to -$15.4 million in 2024, then spiked by 115.17% to $4.1 million in 2025.
  • Its EBITDA stands at $4.1 million for Q3 2025, versus -$71.0 million for Q2 2025 and -$5.4 million for Q1 2025.